Serum Fructosamine, Total Cholesterol, and High-Density Lipoprotein in Children with Asthma during Glucocorticoid Treatment
| Autor: | A. J. Schou, O. D. Wolthers |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Budesonide
medicine.medical_specialty Article Subject business.industry medicine.disease Placebo chemistry.chemical_compound High-density lipoprotein Endocrinology chemistry Internal medicine Clinical Study Prednisolone medicine business Adverse effect Glucocorticoid medicine.drug Asthma Lipoprotein |
| Zdroj: | ISRN Allergy |
| ISSN: | 2090-553X 2090-5521 |
| DOI: | 10.5402/2011/295124 |
| Popis: | Background/Aims. Glucocorticoids may have adverse effects on carbohydrate and lipid metabolism. The present study was conducted to investigate possible effects on carbohydrate and lipid metabolism of inhaled and oral glucocorticoids in children with asthma. Methods. Two randomised controlled trials with blinded crossover designs were performed. Active treatment was 400 μg inhaled budesonide or 5 mg prednisolone orally daily during one week. The budesonide trial included 17 and the prednisolone trial 20 school children. Serum fructosamine, total cholesterol and high-density lipoprotein were assessed. Results. Serum fructosamine was increased during active treatment (prednisolone 252.3 μM versus placebo 247.3 μM; P = 0.03 and budesonide 228.1 μM versus no treatment 223.1 μM; P = 0.02). Total cholesterol and high-density lipoprotein were not statistically significantly increased. Conclusion. Short-term treatment with oral prednisolone and inhaled budesonide may adversely affect mean blood glucose concentration. Possible long-term consequences require further investigations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|